title: Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
abstract: Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related deaths worldwide. The high mortality of ESCC is mainly due to late diagnosis. Current detection methods have their own weakness, including high costs and invasive procedures. MicroRNA assays are shown to have great potential to be accurate and noninvasive methods for ESCC screening. In this study, we selected 3 microRNAs, miR-10b, miR-29c, and miR-205, to assess their diagnostic value in ESCC screening. Fifty ESCC patients and 50 healthy controls are recruited in our study. Blood samples are collected from the total 100 participants. MicroRNAs were extracted from serum and quantified by qRT-PCR, which their relative expressions were normalized by internal control, U6 snRNA. Statistical analyses were conducted to compare microRNAs level as well as other clinical characteristics between 2 groups. The levels of serum miR-29c and miR-205 were significantly downregulated in ESCC patients compared with healthy volunteers. In contrast, ESCC patients appeared to have a higher level of miR-10b than healthy controls. ROC curve analyses revealed that the AUC value for miR-10b, miR-29c, and miR-205 were 0.85 (95% CI: 0.79-0.93; sensitivity = 76%; specificity = 84%), 0.72 (95% CI: 0.62-0.82; sensitivity = 68%; specificity = 68%), and 0.72 (95% CI: 0.62-0.83; sensitivity = 70%; specificity = 64%), respectively, suggesting that miR-10b, miR-29c, and miR-205 have great potential to be noninvasive screening tools for ESCC detection.
authors.affiliation: From the Department of Pharmacy, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China (HX); School of Life Science and Technology, Harbin Institute of Technology, Harbin, China (YY); School of Public Health, Harbin Medical University, Harbin, China (FM); Department of Neuro-Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA (XQ); Department of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China (XJ, ZG); The Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, China (XL, ZG); Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA (ZG); College of Life Sciences, Northeast Agricultural University, Harbin, China (LG); and Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA (LG).
authors.forename: Hang
authors.initials: H
authors.lastname: Xu
authors.forename: Yuanfei
authors.initials: Y
authors.lastname: Yao
authors.forename: Fanyu
authors.initials: F
authors.lastname: Meng
authors.forename: Xu
authors.initials: X
authors.lastname: Qian
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Jiang
authors.forename: Xiaoxi
authors.initials: X
authors.lastname: Li
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Gao
authors.forename: Lu
authors.initials: L
authors.lastname: Gao
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000175:diagnosis / Q000235:genetics*; D004938:Esophageal Neoplasms / Q000097:blood / Q000175:diagnosis / Q000235:genetics*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; D012334:RNA, Neoplasm; C547183:MIRN10 microRNA, human; C534425:MIR205, human; C532045:MIRN29a microRNA, human